Tepezza

Hand passing wad of bills to other hand
Biotech

Sling reels in $123M to fund oral Tepezza rival through ph. 3

The Michigan-based biotech will use the funds to advance linsitinib as the company began dosing patients in its phase 3 thyroid eye disease study.
Marissa Russo Sep 16, 2026 7:00am
Close-up of human eye

Viridian’s Tepezza rival racks up another ph. 3 win

May 5, 2026 8:00am
Closeup of blue eye on black background

Viridian’s Tepezza rival scores ph. 3 win, but investors unsure

Mar 30, 2026 10:11am
eye eyeball eye art

Sling's oral Tepezza rival hits goal in thyroid eye disease

Jan 14, 2025 8:16am
eye eyeball eye art

Viridian eye disease phase 3 hits, advancing push to rival Amgen

Sep 10, 2024 8:10am
Businessman puts his box of his belongs on the desk and holds a white letter

Acelyrin loses interest in izokibep, lays off 3rd of staff

Aug 13, 2024 4:00pm